27 clinical trials found.
-
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced
The purpose of this study is to learn more about the effects of a drug called AMG 510 in patients with advanced solid tumors with ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors Including RET Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-001)
The purpose of this research study is to determine the safety of an investigational treatment called LOXO-292. LOXO-292 is an oral investigational drug that may ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, Phase 1 study which will be conducted in 2 parts: a dose-escalation part and a dose expansion part. Patients with ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
The Selective Personalized Radio-Immunotherapy for locally advanced NSCLC Trial (SPRINT)
The purpose of this study is to determine if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
Phase III randomized double-blind placebo-controlled multi-centre study assessing the efficacy and safety of durvalumab versus placebo as treatment following SBRT in patients with Stage I/II non small cell lung cancer.
The purpose of this study by AstraZeneca AB is to find out if the medication called durvalumab will work and be safe for the treatment ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TRQ15-01 administered i.v. in patients with relapsed ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A PHASE III DOUBLE-BLINDED MULTICENTER RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a combination ...Phase
Interventional
TRIAL ROLE: Sub Investigator
